FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017107943> ?p ?o ?g. }

• W2017107943 endingPage "1439" @default.
• W2017107943 startingPage "1432" @default.
• W2017107943 abstract "Risperidone (RIS), an atypical antipsychotic drug, is used for the treatment of psychoses associated with schizophrenia and other psychiatric disorders in adult and pediatric populations. An oral dispersible tablet formulation of risperidone has been developed. This study was conducted to provide support for marketing authorization of this drug in China.This study was designed to compare the pharmacokinetic (PK) properties and bioavailability of 2 RIS formulations-the dispersible formulation (test) and a branded formulation (reference) in healthy male Chinese volunteers.This single-dose, randomized-sequence, open-label, 2-period crossover study involved 22 healthy male Chinese volunteers. Equal numbers of eligible participants were randomly assigned to receive either the test drug (2 mg) or the same dose of the reference formulation, followed by a 2-week washout period and administration of the alternate formulation. The study drugs were administered after a 10-hour overnight fast. Blood samples were collected before dosing and at 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, and 96 hours after dosing. Plasma concentrations of RIS and its active metabolite, 9-hydroxyrisperidone (9-OH-RIS), were measured using LC-MS/MS. The safety profile was evaluated by recording adverse events (AEs), assessed using physical examination including vital signs, spontaneous reporting, and clinical laboratory results. The 2 formulations were considered to have met the requirements for bioequivalence if the 90% CIs for the log-transformed C(max) and AUC values were within the predetermined ranges of 75% to 133% and 80% to 125%, respectively, according to the guidelines of the State Food and Drug Administration (SFDA) of China.All 22 volunteers (mean [SD] age, 22.2 [1.98] years; weight, 64.07 [5.93] kg; height, 173 [5] cm; and body mass index, 21.2 [1.67] kg/m(2)) that were enrolled completed the study. For RIS, the 90% CIs for the ratios of C(max), AUC(0-t), and AUC(0-∞) were 93.2% to 116.7%, 97.9% to 111.3%, and 98.0% to 111.6%, respectively. For 9-OH-RIS, the 90% CIs were 95.8% to 113.9%, 100.2% to 109.7%, and 100.5% to 110.3%, respectively. All values were within the predetermined bioequivalence range. Seven AEs were reported somnolence (4 subjects [9.1%]) and dizziness (3 subjects [6.8%]). All AEs were transient and considered mild by physicians.The test (dispersible) and reference tablets met the regulatory criteria for bioequivalence as defined by the SFDA. Both formulations were well tolerated. Chinese Clinical Trials registration number: ChiCTR-TRC-12001996." @default.
• W2017107943 created "2016-06-24" @default.
• W2017107943 creator A5007875050 @default.
• W2017107943 creator A5011853411 @default.
• W2017107943 creator A5018928264 @default.
• W2017107943 creator A5062237980 @default.
• W2017107943 creator A5083936156 @default.
• W2017107943 creator A5090999874 @default.
• W2017107943 date "2012-06-01" @default.
• W2017107943 modified "2023-10-16" @default.
• W2017107943 title "Comparative Fasting Bioavailability of Dispersible and Conventional Tablets of Risperidone: A Single-Dose, Randomized-Sequence, Open-Label, Two-Period Crossover Study in Healthy Male Chinese Volunteers" @default.
• W2017107943 cites W1965037429 @default.
• W2017107943 cites W1965351344 @default.
• W2017107943 cites W1965449788 @default.
• W2017107943 cites W1988216543 @default.
• W2017107943 cites W1998201540 @default.
• W2017107943 cites W1999954638 @default.
• W2017107943 cites W2004687570 @default.
• W2017107943 cites W2007530394 @default.
• W2017107943 cites W2008283765 @default.
• W2017107943 cites W2008622864 @default.
• W2017107943 cites W2016880063 @default.
• W2017107943 cites W2030481736 @default.
• W2017107943 cites W2041959054 @default.
• W2017107943 cites W2059640274 @default.
• W2017107943 cites W2062106705 @default.
• W2017107943 cites W2096775351 @default.
• W2017107943 cites W2157563846 @default.
• W2017107943 doi "https://doi.org/10.1016/j.clinthera.2012.04.027" @default.
• W2017107943 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22595151" @default.
• W2017107943 hasPublicationYear "2012" @default.
• W2017107943 type Work @default.
• W2017107943 sameAs 2017107943 @default.
• W2017107943 citedByCount "10" @default.
• W2017107943 countsByYear W20171079432012 @default.
• W2017107943 countsByYear W20171079432013 @default.
• W2017107943 countsByYear W20171079432014 @default.
• W2017107943 countsByYear W20171079432015 @default.
• W2017107943 countsByYear W20171079432018 @default.
• W2017107943 countsByYear W20171079432020 @default.
• W2017107943 crossrefType "journal-article" @default.
• W2017107943 hasAuthorship W2017107943A5007875050 @default.
• W2017107943 hasAuthorship W2017107943A5011853411 @default.
• W2017107943 hasAuthorship W2017107943A5018928264 @default.
• W2017107943 hasAuthorship W2017107943A5062237980 @default.
• W2017107943 hasAuthorship W2017107943A5083936156 @default.
• W2017107943 hasAuthorship W2017107943A5090999874 @default.
• W2017107943 hasConcept C112705442 @default.
• W2017107943 hasConcept C118552586 @default.
• W2017107943 hasConcept C142724271 @default.
• W2017107943 hasConcept C181389837 @default.
• W2017107943 hasConcept C197934379 @default.
• W2017107943 hasConcept C204787440 @default.
• W2017107943 hasConcept C27081682 @default.
• W2017107943 hasConcept C2776412080 @default.
• W2017107943 hasConcept C2776921671 @default.
• W2017107943 hasConcept C2777288759 @default.
• W2017107943 hasConcept C2778375690 @default.
• W2017107943 hasConcept C2780057945 @default.
• W2017107943 hasConcept C2780494398 @default.
• W2017107943 hasConcept C42404028 @default.
• W2017107943 hasConcept C71924100 @default.
• W2017107943 hasConcept C87813604 @default.
• W2017107943 hasConcept C98274493 @default.
• W2017107943 hasConceptScore W2017107943C112705442 @default.
• W2017107943 hasConceptScore W2017107943C118552586 @default.
• W2017107943 hasConceptScore W2017107943C142724271 @default.
• W2017107943 hasConceptScore W2017107943C181389837 @default.
• W2017107943 hasConceptScore W2017107943C197934379 @default.
• W2017107943 hasConceptScore W2017107943C204787440 @default.
• W2017107943 hasConceptScore W2017107943C27081682 @default.
• W2017107943 hasConceptScore W2017107943C2776412080 @default.
• W2017107943 hasConceptScore W2017107943C2776921671 @default.
• W2017107943 hasConceptScore W2017107943C2777288759 @default.
• W2017107943 hasConceptScore W2017107943C2778375690 @default.
• W2017107943 hasConceptScore W2017107943C2780057945 @default.
• W2017107943 hasConceptScore W2017107943C2780494398 @default.
• W2017107943 hasConceptScore W2017107943C42404028 @default.
• W2017107943 hasConceptScore W2017107943C71924100 @default.
• W2017107943 hasConceptScore W2017107943C87813604 @default.
• W2017107943 hasConceptScore W2017107943C98274493 @default.
• W2017107943 hasFunder F4320325436 @default.
• W2017107943 hasIssue "6" @default.
• W2017107943 hasLocation W20171079431 @default.
• W2017107943 hasLocation W20171079432 @default.
• W2017107943 hasOpenAccess W2017107943 @default.
• W2017107943 hasPrimaryLocation W20171079431 @default.
• W2017107943 hasRelatedWork W2004325424 @default.
• W2017107943 hasRelatedWork W2017107943 @default.
• W2017107943 hasRelatedWork W2353450705 @default.
• W2017107943 hasRelatedWork W2356170336 @default.
• W2017107943 hasRelatedWork W2357220270 @default.
• W2017107943 hasRelatedWork W2373452970 @default.
• W2017107943 hasRelatedWork W2374069256 @default.
• W2017107943 hasRelatedWork W2380091905 @default.
• W2017107943 hasRelatedWork W2380433639 @default.
• W2017107943 hasRelatedWork W2391752688 @default.
• W2017107943 hasVolume "34" @default.

• next